High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy.
Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL.
J Clin Oncol. 2009 May 1;27(13):2151-6. Epub 2009 Apr 6.
PMID: 19349547
DOI: 10.1200/JCO.2008.19.6162
Conclusion Vitamin D deficiency is highly prevalent in women with breast cancer. The current recommended dietary allowance of vitamin D is too low to increase serum 25-OHD greater than 30 ng/mL. Optimal dosing for bone health and, possibly, improved survival has yet to be determined.
Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer.
Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N.
J Clin Oncol. 2009 Aug 10;27(23):3757-63. Epub 2009 May 18.
PMID: 19451439
DOI: 10.1200/JCO.2008.20.0725
Conclusion Vitamin D deficiency may be associated with poor outcomes in breast cancer.
Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer.
Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, Fuchs CS.
J Clin Oncol. 2008 Jun 20;26(18):2984-91.
PMID: 18565885
DOI: 10.1200/JCO.2007.15.1027
Conclusion Among patients with colorectal cancer, higher prediagnosis plasma 25(OH)D levels were associated with a significant improvement in overall survival. Further study of the vitamin D pathway and its influence on colorectal carcinogenesis and cancer progression is warranted.
Caution regarding 25-hydroxyvitamin D monitoring in women with breast cancer.
Chlebowski RT.
J Clin Oncol. 2009 Aug 20;27(24):e72-3; author reply e74. Epub 2009 Jul 20.
PMID: 1962047